BioCentury | Mar 30, 2021
Finance

March 30 Quick Takes: BioNTech anticipates €9.8B year; plus Immune-Onc, Amgen-Rodeo, Stuart, Bond

...Sales of the COVID-19 vaccine were €270.5 million in 2020.Oceanpine leads $73M series B for Immune-OncImmune-Onc...
BioCentury | Oct 8, 2019
Company News

Management tracks: BioMarin's first chief scientific strategy officer; plus Ascletis, Grail, Aerie and more

...James Jett to share the position of CMO with Steven Springmeyer. Jett was CMO at Oncimmune Holdings plc...
BioCentury | Jan 5, 2018
Company News

Oncimmune to grant Genostics rights to EarlyCDT diagnostic platform

...Group Holdings Ltd. (Hong Kong, China) exclusive rights to develop and commercialize products related to Oncimmune’s...
...six tumor-related antigens to detect lung cancer. Genostics will invest £10 million ($13.5 million) in Oncimmune...
...Oncimmune Holdings plc (LSE:ONC), Nottingham, U.K. Gene Group Holdings Ltd., Hong Kong, China Business: Diagnostic, Cancer Jaime De Leon EarlyCDT-Lung Oncimmune Holdings plc Gene...
BioCentury | Jul 11, 2016
Finance

Ground up

...Inc. (NASDAQ:RETA) 5/26/16 $69.6 $245.6 $440.9 80% Merus N.V. (NASDAQ:MRUS) 5/18/16 $61.4 $160.5 $128.2 -20% Oncimmune Holdings plc...
BioCentury | May 23, 2016
Financial News

Oncimmune completes IPO

Oncimmune Holdings plc (LSE:ONC), Nottingham, U.K. Business: Diagnostic Date completed: 2016-05-18 Type: IPO Raised: L11 million ($15.8 million) Shares: 8.5 million Price: 130p Shares after offering: 51 million WIR Staff Diagnostic...
BioCentury | Apr 25, 2016
Financial News

Oncimmune proposes IPO

...Type: IPO To be raised: About L11 million ($15.6 million) Shares: TBD Price: TBD Note: Oncimmune...
BioCentury | Jan 27, 2014
Company News

Innovative Diagnostic Laboratory LLP sales and marketing update

...antigens. Health Diagnostic has exclusive, U.S. rights to market and perform the EarlyCDT-Lung test from Oncimmune...
BioCentury | Oct 28, 2013
Company News

Health Diagnostic Laboratory, Oncimmune deal

...Health Diagnostic acquired "substantially all" of the assets of Oncimmune's Oncimmune USA LLC subsidiary. As part...
...As part of the deal, all 25 employees of the subsidiary will join Health Diagnostic. Oncimmune...
...disclose details, and Oncimmune could not be reached. Health Diagnostic Laboratory Inc. , Richmond, Va. Oncimmune...
BioCentury | Nov 19, 2012
Company News

Enzo sales and marketing update

...Enzo has rights from Oncimmune Ltd. (Nottingham, U.K.) to market the test in the regions. Oncimmune...
BioCentury | Apr 2, 2012
Clinical News

EarlyCDT-Lung update

...By year end, Oncimmune will begin a prospective screening trial to evaluate the cost-effectiveness of EarlyCDT-Lung...
...GBU4-5 (GBU4-5) , annexin A1 (ANXA1) and SRY (sex determining region Y)-box 2 (SOX2) . Oncimmune...
...samples, licensed non-exclusive rights to the annexin biomarkers used in the test from Proteome Sciences. Oncimmune...
Items per page:
1 - 10 of 13
BioCentury | Mar 30, 2021
Finance

March 30 Quick Takes: BioNTech anticipates €9.8B year; plus Immune-Onc, Amgen-Rodeo, Stuart, Bond

...Sales of the COVID-19 vaccine were €270.5 million in 2020.Oceanpine leads $73M series B for Immune-OncImmune-Onc...
BioCentury | Oct 8, 2019
Company News

Management tracks: BioMarin's first chief scientific strategy officer; plus Ascletis, Grail, Aerie and more

...James Jett to share the position of CMO with Steven Springmeyer. Jett was CMO at Oncimmune Holdings plc...
BioCentury | Jan 5, 2018
Company News

Oncimmune to grant Genostics rights to EarlyCDT diagnostic platform

...Group Holdings Ltd. (Hong Kong, China) exclusive rights to develop and commercialize products related to Oncimmune’s...
...six tumor-related antigens to detect lung cancer. Genostics will invest £10 million ($13.5 million) in Oncimmune...
...Oncimmune Holdings plc (LSE:ONC), Nottingham, U.K. Gene Group Holdings Ltd., Hong Kong, China Business: Diagnostic, Cancer Jaime De Leon EarlyCDT-Lung Oncimmune Holdings plc Gene...
BioCentury | Jul 11, 2016
Finance

Ground up

...Inc. (NASDAQ:RETA) 5/26/16 $69.6 $245.6 $440.9 80% Merus N.V. (NASDAQ:MRUS) 5/18/16 $61.4 $160.5 $128.2 -20% Oncimmune Holdings plc...
BioCentury | May 23, 2016
Financial News

Oncimmune completes IPO

Oncimmune Holdings plc (LSE:ONC), Nottingham, U.K. Business: Diagnostic Date completed: 2016-05-18 Type: IPO Raised: L11 million ($15.8 million) Shares: 8.5 million Price: 130p Shares after offering: 51 million WIR Staff Diagnostic...
BioCentury | Apr 25, 2016
Financial News

Oncimmune proposes IPO

...Type: IPO To be raised: About L11 million ($15.6 million) Shares: TBD Price: TBD Note: Oncimmune...
BioCentury | Jan 27, 2014
Company News

Innovative Diagnostic Laboratory LLP sales and marketing update

...antigens. Health Diagnostic has exclusive, U.S. rights to market and perform the EarlyCDT-Lung test from Oncimmune...
BioCentury | Oct 28, 2013
Company News

Health Diagnostic Laboratory, Oncimmune deal

...Health Diagnostic acquired "substantially all" of the assets of Oncimmune's Oncimmune USA LLC subsidiary. As part...
...As part of the deal, all 25 employees of the subsidiary will join Health Diagnostic. Oncimmune...
...disclose details, and Oncimmune could not be reached. Health Diagnostic Laboratory Inc. , Richmond, Va. Oncimmune...
BioCentury | Nov 19, 2012
Company News

Enzo sales and marketing update

...Enzo has rights from Oncimmune Ltd. (Nottingham, U.K.) to market the test in the regions. Oncimmune...
BioCentury | Apr 2, 2012
Clinical News

EarlyCDT-Lung update

...By year end, Oncimmune will begin a prospective screening trial to evaluate the cost-effectiveness of EarlyCDT-Lung...
...GBU4-5 (GBU4-5) , annexin A1 (ANXA1) and SRY (sex determining region Y)-box 2 (SOX2) . Oncimmune...
...samples, licensed non-exclusive rights to the annexin biomarkers used in the test from Proteome Sciences. Oncimmune...
Items per page:
1 - 10 of 13